It is the powerful combination of delivery and pioneering access for patients that makes us proud to be part of the Sandoz growth journey ... Biosimilars represented 27% of total net sales (Q1 2024: ...

Sandoz has signed a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of oncology therapy, ipilimumab (Bristol-Myers Squibb’s Yervoy). The agreement is ...

Etanercept is a biologic medicine used to treat various inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz ...

Etanercept is a biologic medicine used to treat a range of disabling inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors ...

(RTTNews) - Sandoz (SDZNY) has initiated an antitrust lawsuit in the United States against Amgen, Inc. (AMGN), accusing the company of maintaining its dominant market position for the blockbuster ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept). The drug was ...

Sandoz signs 10-year agreement with partner Delpharm, a global pharmaceutical developer and contract manufacturer Agreement will secure a reliable supply of affordable, quality sterile injectables ...

Investing.com -- Sandoz (SIX:SDZ) Group AG reported its full-year 2024 financial results, showing figures largely in line with expectations. However, the company’s 2025 guidance points to a ...

Sandoz is one of the largest off-patent pharmaceutical manufacturers in the world. It generates roughly 75% of sales from generic drugs with the remainder from biosimilars and has a significant ...

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion ... Emasan AG sold 26.5 million shares at a price of 98.25 Swiss francs in an accelerated bookbuilt offering ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 billion). The Sandoz Family Foundation, through the vehicle Emasan AG ...

Sandoz Group said it would pay $275 million to settle claims from some plaintiffs in a generics drug pricing antitrust lawsuit in the U.S. The Swiss generics-medicine company said Tuesday that it ...